Next-Gen RBD COVID Vaccine Has Strong, Fast Variant Defense
Second-generation COVID-19 Vaccine
Tags: University of Melbourne, Australia, Healthcare & Lifesciences
The second-generation COVID-19 vaccine, developed at the Doherty Institute for Infection and Immunity, focuses on the receptor-binding domain (RBD) of SARS-CoV-2, enhancing the immune response against variants. This RBD vaccine, shown to be safe and effective in Phase 1 clinical trials, is stable, easily produced, and adaptable to new strains, offering global distribution advantages, especially in regions with limited cold storage. It generates robust immunity, even against challenging variants like Omicron, and can be rapidly updated for emerging strains.
IP Type or Form Factor: Patent Pending; Platform
TRL: 6 - prototype validated in intended environment
Industry or Tech Area: Vaccines; Biotechnology
